Barclays Forecasts Strong Price Appreciation for Iovance Biotherapeutics (NASDAQ:IOVA) Stock

Iovance Biotherapeutics (NASDAQ:IOVA) had its target price lifted by Barclays from $10.00 to $11.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price objective indicates a potential upside of 190.24% from the stock’s previous close.

Other analysts have also recently issued reports about the company. HC Wainwright dropped their price target on Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, October 29th. The Goldman Sachs Group reissued a “sell” rating and set a $2.00 target price on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. Chardan Capital reduced their target price on shares of Iovance Biotherapeutics from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Citizens Jmp raised shares of Iovance Biotherapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research report on Wednesday. Six investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Iovance Biotherapeutics Stock Performance

Shares of IOVA stock opened at $3.79 on Wednesday. Iovance Biotherapeutics has a 52 week low of $1.64 and a 52 week high of $5.64. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -3.38 and a beta of 0.76. The company has a 50-day simple moving average of $2.69 and a 200 day simple moving average of $2.42.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.04. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%. The firm had revenue of $86.77 million for the quarter, compared to analysts’ expectations of $81.61 million. Sell-side analysts forecast that Iovance Biotherapeutics will post -1.24 EPS for the current year.

Institutional Investors Weigh In On Iovance Biotherapeutics

A number of large investors have recently bought and sold shares of IOVA. Royal Bank of Canada increased its holdings in Iovance Biotherapeutics by 161.2% in the 1st quarter. Royal Bank of Canada now owns 522,887 shares of the biotechnology company’s stock valued at $1,740,000 after buying an additional 322,680 shares during the period. AQR Capital Management LLC increased its stake in Iovance Biotherapeutics by 279.0% in the first quarter. AQR Capital Management LLC now owns 59,540 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 43,829 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Iovance Biotherapeutics by 30.5% in the first quarter. Goldman Sachs Group Inc. now owns 5,571,902 shares of the biotechnology company’s stock valued at $18,554,000 after acquiring an additional 1,301,846 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Iovance Biotherapeutics by 202.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock valued at $19,239,000 after purchasing an additional 3,869,617 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in Iovance Biotherapeutics by 112.1% during the second quarter. Envestnet Asset Management Inc. now owns 47,466 shares of the biotechnology company’s stock worth $82,000 after purchasing an additional 25,083 shares during the last quarter. 77.03% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Reported strong Q4 and FY2025 results: 61% year‑over‑year revenue growth to $264M and Q4 product revenue of roughly $87M; Q4 EPS loss was narrower than expected and revenue beat consensus — this underpins the recent rally. Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success
• Positive Sentiment: Amtagvi (lifileucel) is now an approved commercial product with accelerating adoption — company reported product sales growth (sales up ~30–33% in Q4) and lifileucel has received Fast Track designation in second‑line NSCLC; management plans registrational sarcoma studies after strong early responses. This shifts Iovance toward execution and revenue growth rather than a pure pipeline bet. Iovance FDA Approval Shifts Lifileucel From Pipeline Bet To Execution Test
• Positive Sentiment: Encouraging sarcoma data and 50% ORR in early cohorts prompted plans for a registrational sarcoma trial — clinical validation of TIL therapy in new indications supports upside to revenue and long‑term value. Iovance Announces Positive Results for TIL in Soft Tissue Sarcomas
• Positive Sentiment: Analysts updated models and ratings after the print — Barclays raised its target and kept an overweight stance; HC Wainwright raised FY2026/27 estimates and maintains a Buy with a higher target, and other firms issued buy/outperform notes — analyst support likely amplified buying. Analyst Coverage Changes
• Positive Sentiment: Operational story: coverage highlighting the Philadelphia manufacturing/scale‑up helps explain the stock’s multi‑week surge — investors are pricing in improved capacity to supply Amtagvi. Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why
• Neutral Sentiment: Management scheduled investor presentations at TD Cowen and Barclays conferences in early March — useful for more detail but not immediate catalysts. Iovance to Present at Upcoming Conferences
• Neutral Sentiment: Unusually large options volume and heavy intraday trading indicate speculative positioning and rapid repricing; this raises liquidity but not a directional fundamental change. Options Volume Report
• Negative Sentiment: Short interest ballooned (~36.9% of float, short‑interest ratio ~14.6 days) — while this can fuel squeezes on rallies, it also increases downside pressure and volatility when momentum fades or profit taking occurs.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.